Table 2.

Treatment and Outcome characteristics of uterine sarcoma patients stratified on the histological type (n = 40)

Characteristics	All patients (n = 40)	u-LMS (n = 16)	HGESS (n = 10)	LGESS (n = 8)	Other histologic subtypes (n = 6)	p-value
Primary surgery type, n(%)
TAH + BSO	12 (30.0)	6 (50.0)	3 (25.0)	2 (16.67)	1 (8.33)
TAH + BSO + PLND	15 (37.50)	3 (20.0)	5 (33.33)	4 (26.67)	3 (20.0)	0.045
TAH + BS + ovarian conservation	7 (17.50)	6 (85.71)	1 (14.29)	0 (0.0)	0 (0.0)
Myomectomy	3 (7.50)	1 (33.33)	0 (0.0)	2 (66.67)	0 (0.0)
Surgery not done	3 (7.50)	0 (0.0)	1 (33.33)	0 (0.0)	2 (66.67)
Residual disease after primary surgery, n(%)
Present	8 (21.62)	6 (75.0)	2 (25.0)	0 (0.0)	0 (0.0)	0.128
Absent	29 (78.38)	10 (34.48)	7 (24.14)	8 (27.59)	4 (13.79)
Adjuvant chemotherapy received, n(%)
Yes	24 (60.0)	7 (29.17)	6 (25.0)	5 (20.83)	6 (25.0)	0.123
No	16 (40.0)	9 (56.25)	4 (25.0)	3 (18.75)	0 (0.0)
Chemotherapeutic regimen, n(%)
Ifosfamide	1 (4.17)	1 (100.0)	0 (0.0)	0 (0.0)	0 (0.0)
Doxorubicin	2 (8.33)	1 (50.0)	0 (0.0)	0 (0.0)	1 (50.0)	0.760
Doxorubicin + Ifosfamide	5 (20.83)	2 (40.00)	2 (40.00)	1 (20.0)	0 (0.0)
Gemcitabine + Docetaxel	16 (66.67)	5 (31.25)	6 (37.5)	1 (6.25)	4 (25.0)
Number of Cycles received n (%)
3	5 (20.83)	1 (20.0)	2 (40.0)	0 (0.0)	2 (40.0)
4	13 (54.17)	7 (53.85)	3 (23.08)	2 (15.38)	1 (7.69)
6	6 (25.0)	1 (16.67)	3 (50.0)	0 (0.0)	2 (33.33)	0.311
Adjuvant Radiation Therapy, n(%)
Yes	9 (22.50)	4 (44.44)	2 (22.22)	2 (22.22)	1 (11.11)	0.971
No	31 (77.50)	12 (38.71)	8 (25.81)	6 (19.35)	5 (16.13)
Hormonal therapy, n(%)
Yes	5 (12.50)	0 (0.0)	2 (40.0)	3 (60.0)	0 (0.0)	0.042
No	35 (87.50)	16 (45.71)	8 (22.86)	5 (14.29)	6 (17.14)
Recurrences, n(%)
Yes	18 (45.0)	5 (27.78)	4 (22.22)	5 (27.78)	4 (22.22)	0.327
No	22(55.0)	11 (50.0)	6 (27.27)	3 (13.64)	2 (9.09)
Follow-up, n(%)
Alive with disease	12(30.0)	4 (33.33)	2(16.67)	5 (41.67)	1 (8.33)
Alive with remission	22 (55.0)	11(50.0)	6 (27.27)	3 (13.64)	2 (9.09)	0.049
Died	6 (15.0)	1(16.67)	2(33.33)	0 (0.0)	3 (50.0)